D2/D3 Receptor Agonism: Paving the Way for a New Therapeutic Target for Taste Disorders in Parkinson's Disease and Other Conditions?
Elisa MantovaniStefano TamburinPublished in: The international journal of neuropsychopharmacology (2022)
Chemosensory (i.e., olfaction and taste) dysfunction is common in neurodegenerative (e.g., Parkinson's disease, Alzheimer's disease, and dementia), psychiatric (e.g., depression, bipolar disorders, other conditions), and postinfectious (i.e., long COVID) diseases and in the elderly. Despite its impact on patients' quality of life, no established treatment for taste disorders exists so far. A recent report on the effect of pramipexole, a D2/D3 agonist, on taste performance in healthy participants provides support for a new potential therapeutic target for taste dysfunction to be tested in future randomized, placebo-controlled, clinical trials across several populations reporting gustatory symptoms.
Keyphrases
- placebo controlled
- clinical trial
- double blind
- end stage renal disease
- oxidative stress
- coronavirus disease
- sars cov
- phase ii
- newly diagnosed
- phase iii
- ejection fraction
- chronic kidney disease
- open label
- sleep quality
- prognostic factors
- emergency department
- cognitive impairment
- radiation therapy
- current status
- patient reported outcomes
- peritoneal dialysis
- genetic diversity
- replacement therapy